I had one once. It was sweet to sell during the blackout, especially when the company went belly up not too long after. Of course, there was the layoff after that.........
I should do that, but many companies have their own ways of looking for GPCR targets. As for fueling pipelines, I don't value them particularly until they put a drug candidate in Phase II or III. Lot of dead bodies along the road of drug discovery.
"Soft bashing" is easy if sales aren't meeting expectations. Once ( or if) they do, it will go away.
Not sure what you meant by your statement "40-50% of marketed drugs have not been through the process that Belviq and ARNA's pipeline drugs have been through". I hope you weren't implying that other pharmas aren't rigorous in their approach to science, because that would be wrong.
Why are you guys so fixated on GPCRs? There's no magic there-something like 40-50% of marketed drugs work via these receptors. From a drug development POV that's good, as they are expressed on the surface of cells and thus the drug doesn't need to get through the cell membrane to exert its effect. I've worked on drugs for several different GPCRs over my career. Sheesh. Get real.
Very little in there and not particularly toxic. If you want to argue that it gets converted into benzene in the body, that is more toxic, but the levels are barely detectable. The worst effects are the well documented ones- corrosion of the enamel and contributing to obesity/diabetes, which is a plus from ARNA stockholders.
So what you are saying is that diet and exercise plus Belviq should have a different long term outcome, right? As a long I'd love to see someone taking the drug for years, but I wonder if Belviq can alter someone's perception of food in the long run to change the typical yo yo effect seen in those dieting.
Maybe phen fen is a better example (mid 90s) I think they got to a couple of hundred million in a year or 2.
It's about market creation. Take a look at the former #1 and #2 drugs Lipitor and Plavix-statins really are only indicated for those with heart disease already (maybe), while Plavix has a high non responder rate and works mainly post heart attack. Both were heavily marketed and widely prescribed, making their sales high.
Oh, and Vivus investors might wake up one day to a cleft palate, whether because someone took the drug incorrectly, or by chance.
That is a possibilty-could also be tarred by a 'side effect' unrelated to the drug, which would still sink the stock.
The first time it happens, whether Q's fault or not, that will be the end of VVUS, if they are still around then.
Sectorwide drop, and if so, why? Thouhgts?
No , he would risk the wrath of the AMT if he held them into 2015. Better to use the proceeds to buy stock now to show confidence. What was his strike price on the options, anyway?
Oh right, forgot that, we had some chronic pain models like that too. Thanks.